{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T10:22:07Z","timestamp":1768904527913,"version":"3.49.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2019,10,16]],"date-time":"2019-10-16T00:00:00Z","timestamp":1571184000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,10,16]],"date-time":"2019-10-16T00:00:00Z","timestamp":1571184000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100010795","name":"Chugai Pharmaceutical","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010795","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003769","name":"Eisai","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003769","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008897","name":"Janssen Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013170","name":"Ono Pharmaceutical","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013170","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Int"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1007\/s00296-019-04464-9","type":"journal-article","created":{"date-parts":[[2019,10,16]],"date-time":"2019-10-16T08:03:13Z","timestamp":1571212993000},"page":"217-225","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["The family history of rheumatoid arthritis in anti-cyclic citrullinated peptide antibody-positive patient is not a predictor of poor clinical presentation and treatment response with modern classification criteria and treatment strategy: the ANSWER cohort study"],"prefix":"10.1007","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7896-3937","authenticated-orcid":false,"given":"Koichi","family":"Murata","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9241-060X","authenticated-orcid":false,"given":"Motomu","family":"Hashimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0810-4221","authenticated-orcid":false,"given":"Wataru","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7244-7715","authenticated-orcid":false,"given":"Yonsu","family":"Son","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7299-2884","authenticated-orcid":false,"given":"Hideki","family":"Amuro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3183-4193","authenticated-orcid":false,"given":"Koji","family":"Nagai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0065-929X","authenticated-orcid":false,"given":"Tohru","family":"Takeuchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0773-7238","authenticated-orcid":false,"given":"Masaki","family":"Katayama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6831-8205","authenticated-orcid":false,"given":"Yuichi","family":"Maeda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2426-1024","authenticated-orcid":false,"given":"Kosuke","family":"Ebina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8000-3196","authenticated-orcid":false,"given":"Ryota","family":"Hara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3021-183X","authenticated-orcid":false,"given":"Sadao","family":"Jinno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3120-1273","authenticated-orcid":false,"given":"Akira","family":"Onishi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5981-4648","authenticated-orcid":false,"given":"Kosaku","family":"Murakami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8942-2933","authenticated-orcid":false,"given":"Masao","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1827-382X","authenticated-orcid":false,"given":"Hiromu","family":"Ito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0016-2053","authenticated-orcid":false,"given":"Tsuneyo","family":"Mimori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0802-1255","authenticated-orcid":false,"given":"Shuichi","family":"Matsuda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,10,16]]},"reference":[{"key":"4464_CR1","doi-asserted-by":"publisher","first-page":"2023","DOI":"10.1016\/S0140-6736(16)30173-8","volume":"388","author":"JS Smolen","year":"2016","unstructured":"Smolen JS, Aletaha D, McInnes IB (2016) Rheumatoid arthritis. Lancet 388:2023\u20132038","journal-title":"Lancet"},{"key":"4464_CR2","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1038\/nature12873","volume":"506","author":"Y Okada","year":"2014","unstructured":"Okada Y, Wu D, Trynka G et al (2014) Genetics of rheumatoid arthritis contributes to biology and drug discovery. Nature 506:376\u2013381","journal-title":"Nature"},{"key":"4464_CR3","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1038\/nrrheum.2016.52","volume":"12","author":"T Frisell","year":"2016","unstructured":"Frisell T, Saevarsdottir S, Askling J (2016) Family history of rheumatoid arthritis: an old concept with new developments. Nat Rev Rheumatol 12:335\u2013343","journal-title":"Nat Rev Rheumatol"},{"key":"4464_CR4","doi-asserted-by":"publisher","first-page":"2773","DOI":"10.1002\/art.38097","volume":"65","author":"T Frisell","year":"2013","unstructured":"Frisell T, Holmqvist M, K\u00e4llberg H et al (2013) Familial risks and heritability of rheumatoid arthritis: role of rheumatoid factor\/anti-citrullinated protein antibody status, number and type of affected relatives, sex, and age. Arthritis Rheum 65:2773\u20132782","journal-title":"Arthritis Rheum"},{"key":"4464_CR5","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1136\/annrheumdis-2013-203947","volume":"74","author":"AH Hensvold","year":"2015","unstructured":"Hensvold AH, Magnusson PKE, Joshua V et al (2015) Environmental and genetic factors in the development of anticitrullinated protein antibodies (ACPAs) and ACPA-positive rheumatoid arthritis: an epidemiological investigation in twins. Ann Rheum Dis 74:375\u2013380","journal-title":"Ann Rheum Dis"},{"key":"4464_CR6","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1002\/art.24385","volume":"60","author":"D Van Der Woude","year":"2009","unstructured":"Van Der Woude D, Houwing-Duistermaat JJ, Toes REM et al (2009) Quantitative heritability of anti-citrullinated protein antibody-positive and anti-citrullinated protein antibody-negative rheumatoid arthritis. Arthritis Rheum 60:916\u2013923","journal-title":"Arthritis Rheum"},{"key":"4464_CR7","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1038\/ng.2462","volume":"44","author":"S Eyre","year":"2012","unstructured":"Eyre S, Bowes J, Diogo D et al (2012) High density genetic mapping identifies new susceptibility loci for rheumatoid arthritis. Nat Genet 44:1336\u20131340","journal-title":"Nat Genet"},{"key":"4464_CR8","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1002\/art.24328","volume":"60","author":"K Hemminki","year":"2009","unstructured":"Hemminki K, Li X, Sundquist J, Sundquist K (2009) Familial associations of rheumatoid arthritis with autoimmune diseases and related conditions. Arthritis Rheum 60:661\u2013668","journal-title":"Arthritis Rheum"},{"key":"4464_CR9","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1136\/annrheumdis-2011-201165","volume":"72","author":"EC Somers","year":"2013","unstructured":"Somers EC, Antonsen S, Pedersen L, S\u00f8rensen HT (2013) Parental history of lupus and rheumatoid arthritis and risk in offspring in a nationwide cohort study: does sex matter? Ann Rheum Dis 72:525","journal-title":"Ann Rheum Dis"},{"key":"4464_CR10","doi-asserted-by":"publisher","first-page":"2247","DOI":"10.1002\/1529-0131(200110)44:10<2247::AID-ART387>3.0.CO;2-Y","volume":"44","author":"SFA Grant","year":"2001","unstructured":"Grant SFA, Thorleifsson G, Frigge ML et al (2001) The inheritance of rheumatoid arthritis in Iceland. Arthritis Rheum 44:2247\u20132254","journal-title":"Arthritis Rheum"},{"key":"4464_CR11","doi-asserted-by":"publisher","first-page":"2618","DOI":"10.1002\/art.39780","volume":"68","author":"SF Ling","year":"2016","unstructured":"Ling SF, Viatte S, Lunt M et al (2016) HLA\u2013DRB1 amino acid positions 11\/13, 71, and 74 are associated with inflammation level, disease activity, and the health assessment questionnaire score in patients with inflammatory polyarthritis. Arthritis Rheumatol 68:2618\u20132628","journal-title":"Arthritis Rheumatol"},{"key":"4464_CR12","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.1001\/jama.2015.3435","volume":"313","author":"S Viatte","year":"2015","unstructured":"Viatte S, Plant D, Han B et al (2015) Association of HLA-DRB1 haplotypes with rheumatoid arthritis severity, mortality, and treatment response. JAMA J Am Med Assoc 313:1645\u20131656","journal-title":"JAMA J Am Med Assoc"},{"key":"4464_CR13","doi-asserted-by":"publisher","first-page":"2038","DOI":"10.1136\/annrheumdis-2013-204050","volume":"73","author":"R Knevel","year":"2014","unstructured":"Knevel R, Klein K, Somers K et al (2014) Identification of a genetic variant for joint damage progression in autoantibody-positive rheumatoid arthritis. Ann Rheum Dis 73:2038\u20132046","journal-title":"Ann Rheum Dis"},{"key":"4464_CR14","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1136\/annrheumdis-2013-203375","volume":"73","author":"DPC de Rooy","year":"2014","unstructured":"de Rooy DPC, Zhernakova A, Tsonaka R et al (2014) A genetic variant in the region of MMP-9 is associated with serum levels and progression of joint damage in rheumatoid arthritis. Ann Rheum Dis 73:1163\u20131169","journal-title":"Ann Rheum Dis"},{"key":"4464_CR15","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1007\/s00281-017-0630-4","volume":"38","author":"S Viatte","year":"2017","unstructured":"Viatte S, Barton A (2017) Genetics of rheumatoid arthritis susceptibility, severity, and treatment response. Semin Immunopathol 38:395\u2013408","journal-title":"Semin Immunopathol"},{"key":"4464_CR16","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1136\/ard.2010.138461","volume":"69","author":"D Aletaha","year":"2010","unstructured":"Aletaha D, Neogi T, Silman AJ (2010) 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology\/European League against rheumatism collaborative initiative. Ann Rheum Dis 69:1580\u20131588","journal-title":"Ann Rheum Dis"},{"key":"4464_CR17","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1136\/annrheumdis-2013-204573","volume":"73","author":"J Smolen","year":"2014","unstructured":"Smolen J, Landew\u00e9 R, Breedveld F et al (2014) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis 73:492\u2013509","journal-title":"Ann Rheum Dis"},{"key":"4464_CR18","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1136\/annrheumdis-2015-207670","volume":"75","author":"T Frisell","year":"2016","unstructured":"Frisell T, Saevarsdottir S, Askling J (2016) Does a family history of RA influence the clinical presentation and treatment response in RA? Ann Rheum Dis 75:1120\u20131125","journal-title":"Ann Rheum Dis"},{"key":"4464_CR19","doi-asserted-by":"publisher","first-page":"e0216624","DOI":"10.1371\/journal.pone.0216624","volume":"14","author":"K Ebina","year":"2019","unstructured":"Ebina K, Hashimoto M, Yamamoto W et al (2019) Drug tolerability and reasons for discontinuation of seven biologics in elderly patients with rheumatoid arthritis\u2014the ANSWER cohort study. PLoS One 14:e0216624","journal-title":"PLoS One"},{"key":"4464_CR20","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1186\/s13075-018-1673-1","volume":"20","author":"M Hashimoto","year":"2018","unstructured":"Hashimoto M, Furu M, Yamamoto W et al (2018) Factors associated with the achievement of biological disease-modifying antirheumatic drug-free remission in rheumatoid arthritis: the ANSWER cohort study. Arthritis Res Ther 20:165","journal-title":"Arthritis Res Ther"},{"key":"4464_CR21","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1186\/s13075-019-1880-4","volume":"21","author":"K Ebina","year":"2019","unstructured":"Ebina K, Hashimoto M, Yamamoto W et al (2019) Drug tolerability and reasons for discontinuation of seven biologics in 4466 treatment courses of rheumatoid arthritis\u2014the ANSWER cohort study. Arthritis Res Ther 21:91","journal-title":"Arthritis Res Ther"},{"key":"4464_CR22","doi-asserted-by":"publisher","first-page":"e0194130","DOI":"10.1371\/journal.pone.0194130","volume":"13","author":"K Ebina","year":"2018","unstructured":"Ebina K, Hashimoto M, Yamamoto W et al (2018) Drug retention and discontinuation reasons between seven biologics in patients with rheumatoid arthritis\u2014the ANSWER cohort study. PLoS One 13:e0194130","journal-title":"PLoS One"},{"key":"4464_CR23","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1002\/art.1780310302","volume":"31","author":"FC Arnett","year":"1988","unstructured":"Arnett FC, Edworthy SM, Bloch DA et al (1988) The american rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31:315\u2013324","journal-title":"Arthritis Rheum"},{"key":"4464_CR24","doi-asserted-by":"publisher","first-page":"2569","DOI":"10.1002\/art.27584","volume":"62","author":"D Aletaha","year":"2010","unstructured":"Aletaha D, Neogi T, Silman AJ et al (2010) 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology\/European League against rheumatism collaborative initiative. Arthritis Rheum 62:2569\u20132581","journal-title":"Arthritis Rheum"},{"key":"4464_CR25","first-page":"1974","volume":"22","author":"A Larsen","year":"1995","unstructured":"Larsen A (1995) How to apply Larsen score in evaluating radiographs of rheumatoid arthritis in longterm studies? J Rheumatol 22:1974\u20131975","journal-title":"J Rheumatol"},{"key":"4464_CR26","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1111\/1756-185X.13428","volume":"22","author":"K Murata","year":"2018","unstructured":"Murata K, Ito H, Hashimoto M et al (2018) Elderly onset of early rheumatoid arthritis is a risk factor for bone erosions, refractory to treatment: KURAMA cohort. Int J Rheum Dis 22:1084\u20131093","journal-title":"Int J Rheum Dis"},{"key":"4464_CR27","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1002\/art.20066","volume":"50","author":"D Jawaheer","year":"2004","unstructured":"Jawaheer D, Lum RF, Amos CI et al (2004) Clustering of disease features within 512 multicase rheumatoid arthritis families. Arthritis Rheum 50:736\u2013741","journal-title":"Arthritis Rheum"},{"key":"4464_CR28","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1136\/annrheumdis-2012-202405","volume":"72","author":"M Umicevic Mirkov","year":"2013","unstructured":"Umicevic Mirkov M, Cui J, Vermeulen SH et al (2013) Genome-wide association analysis of anti-TNF drug response in patients with rheumatoid arthritis. Ann Rheum Dis 72:1375\u20131381","journal-title":"Ann Rheum Dis"},{"key":"4464_CR29","first-page":"962","volume":"28","author":"TR Radstake","year":"2001","unstructured":"Radstake TR, Barrera P, Albers MJ et al (2001) Genetic anticipation in rheumatoid arthritis in Europe. European Consortium on Rheumatoid Arthritis Families. J Rheumatol 28:962\u2013967","journal-title":"J Rheumatol"},{"key":"4464_CR30","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1093\/rheumatology\/39.3.267","volume":"39","author":"TRDJ Radstake","year":"2000","unstructured":"Radstake TRDJ, Barrera P, Albers JMC et al (2000) Familial vs sporadic rheumatoid arthritis (RA). A prospective study in an early RA inception cohort. Rheumatology 39:267\u2013273","journal-title":"Rheumatology"},{"key":"4464_CR31","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1186\/s13075-015-0623-4","volume":"17","author":"C Terao","year":"2015","unstructured":"Terao C, Ohmura K, Kochi Y et al (2015) Anti-citrullinated peptide\/protein antibody (ACPA)-negative RA shares a large proportion of susceptibility loci with ACPA-positive RA: a meta-analysis of genome-wide association study in a Japanese population. Arthritis Res Ther 17:104","journal-title":"Arthritis Res Ther"},{"key":"4464_CR32","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1016\/j.ajhg.2014.02.013","volume":"94","author":"B Han","year":"2014","unstructured":"Han B, Diogo D, Eyre S et al (2014) Fine mapping seronegative and seropositive rheumatoid arthritis to shared and distinct HLA alleles by adjusting for the effects of heterogeneity. Am J Hum Genet 94:522\u2013532","journal-title":"Am J Hum Genet"},{"key":"4464_CR33","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1136\/ard.2009.126821","volume":"70","author":"L Padyukov","year":"2011","unstructured":"Padyukov L, Seielstad M, Ong RTH et al (2011) A genome-wide association study suggests contrasting associations in ACPA-positive versus ACPA-negative rheumatoid arthritis. Ann Rheum Dis 70:259\u2013265","journal-title":"Ann Rheum Dis"},{"key":"4464_CR34","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1038\/nrrheum.2014.16","volume":"10","author":"D Plant","year":"2014","unstructured":"Plant D, Wilson AG, Barton A (2014) Genetic and epigenetic predictors of responsiveness to treatment in RA. Nat Rev Rheumatol 10:329\u2013337","journal-title":"Nat Rev Rheumatol"}],"container-title":["Rheumatology International"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-019-04464-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00296-019-04464-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-019-04464-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,14]],"date-time":"2020-10-14T23:37:36Z","timestamp":1602718656000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00296-019-04464-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,16]]},"references-count":34,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["4464"],"URL":"https:\/\/doi.org\/10.1007\/s00296-019-04464-9","relation":{},"ISSN":["0172-8172","1437-160X"],"issn-type":[{"value":"0172-8172","type":"print"},{"value":"1437-160X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10,16]]},"assertion":[{"value":"16 July 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 October 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 October 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"KMurat received a speaking fee and\/or consulting fee from Eisai Co., Ltd. MH received a research grant and\/or speaker fee from Astellas Pharma Inc., Mitsubishi Tanabe Pharma Corporation, and Bristol-Myers Squibb. TT is affiliated with a department that is financially supported by six pharmaceutical companies (Mitsubishi Tanabe Pharma Corporation, Chugai Pharmaceutical Co. Ltd, AYUMI Pharmaceutical Co., Astellas Pharma, Eisai Co., Ltd., and Takeda Pharmaceutical Company Limited). KN received a research grant and\/or speaker fee from Mitsubishi Tanabe Pharma Corporation, Chugai Pharmaceutical Co., Bristol-Myers Squibb, Eli Lily, Pfizer Inc, Janssen Pharmaceutical K.K., UCB Japan Co. Ltd, and Asahi Kasei Pharma Corporation. TT received a research grant from Chugai Pharmaceutical Co. Ltd, and a speaker fee from Astellas Pharma Inc., Chugai Pharmaceutical Co. Ltd, Mitsubishi Tanabe Pharma Corporation, Bristol-Myers Squibb, Eli Lily, Pfizer Inc, Janssen Pharmaceutical K.K., UCB Japan Co. Ltd, Astellas Pharma, and Asahi Kasei Pharma Corporation. YM received a research grant and\/or speaker fee from Eli Lily, Chugai Pharmaceutical Co. Ltd., Pfizer Inc, Bristol-Myers Squibb and Mitsubishi Tanabe Pharma Corporation. KE received a research grant and\/or speaker fee from Asahi Kasei Corporation, Astellas Pharma Inc., Chugai Pharmaceutical Co. Ltd, Daiichi Sankyo Co. Ltd., Eisai Co., Ltd., Mitsubishi Tanabe Pharma Corporation, Ono Pharmaceutical Co., Ltd., Taisho-toyama, and UCB Japan Co. Ltd. SJ received a research grant and\/or speaker fee from Mitsubishi Tanabe Pharma Corporation, Chugai Pharmaceutical Co., Asahi Kasei Pharma Corporation, Eli Lilly and Company, and AbbVie GK. KMurak has received speaking fees, and\/or consulting fees from Eisai Co. Ltd, Chugai Pharmaceutical Co. Ltd., Pfizer Inc., Bristol-Myers Squibb, Mitsubishi Tanabe Pharma Corporation, UCB Japan Co. Ltd, Daiichi Sankyo Co. Ltd. and Astellas Pharma Inc. M.T. has received research grants and\/or speaker fees from AbbVie GK, Asahi Kasei Pharma Corporation, Astellas Pharma Inc., Bristol-Myers Squibb, Chugai Pharmaceutical Co., Ltd., Eisai Co., Ltd., Eli Lilly and Company, Pfizer Inc., UCB Japan Co., Ltd., Janssen Pharmaceutical K.K., Mitsubishi Tanabe Pharma Corporation, Novartis Pharma K.K., Taisho Pharma Co., Ltd, and Takeda Pharmaceutical Company Limited,. H.I. has received a research grant and\/or speaker fee from Bristol-Myers Squibb, Astellas Pharma Inc., Asahi Kasei Pharma Corporation, and Kyocera Medical Co. TM has received research grants and\/or speakers\u2019 fees from Astellas Pharma Inc., Asahi Kasei Corporation, AYUMI Pharmaceutical Co., Chugai Pharmaceutical Co. Ltd, Daiichi Sankyo Co. Ltd., Eisai Co., Ltd., Mitsubishi Tanabe Pharma Corporation, Pfizer Inc., and Sanofi S.A. SM has received a research grant and\/or speaker fee from Eisai Co., Ltd., Chugai Pharmaceutical Co. Ltd, and Ono Pharmaceutical Co. All other authors have declared no conflicts of interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This observational study was conducted as per the Declaration of Helsinki and was approved by the ethics committees of all seven institutes: Kyoto University (2016-03-24\/approved number R053), Osaka University (2015-11-04\/approved number 15300), Osaka Medical College (2014-07-14\/approved number 1529), Kansai Medical University (2017-11-21\/approved number 2014625), Kobe University (2015-03-20\/approved number 1738), Nara Medial University (2018-01-23\/approved number 1692), and Osaka Red Cross Hospital (2015-09-01\/approved number 644).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"The board of Osaka University Hospital Ethical Committee waived the requirement for patients\u2019 informed consent because of the anonymous nature of the data. Written informed consent was obtained from the participants in other institutes.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"No parts of the manuscript were copied from elsewhere.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Plagiarism"}},{"value":"Part of the data was presented at the 63rd annual general assembly and scientific meeting of the Japan College of Rheumatology and the 5th annual meeting of Japanese Society of Osteoimmunogy.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Prior conference presentation"}},{"value":"Koichi Murata, Motomu Hashimoto, Wataru Yamamoto, Yonsu Son, Hideki Amuro, Koji Nagai, Tohru Takeuchi, Masaki Katayama, Yuichi Maeda, Kosuke Ebina, Ryota Hara, Sadao Jinno, Akira Onishi, Kosaku Murakami, Masao Tanaka, Hiromu Ito, Tsuneyo Mimori and Shuichi Matsuda. Does a family history of RA influence the clinical presentation and treatment response in RA? ANSWER Cohort\u2014[abstract] In: the 63rd annual general assembly and scientific meeting of the Japan College of Rheumatology; 2019 Apr 15\u201314; Kyoto, Kyoto, Japan. Abstract nr P3-007. Koichi Murata, Motomu Hashimoto, Wataru Yamamoto, Yonsu Son, Hideki Amuro, Koji Nagai, Tohru Takeuchi, Masaki Katayama, Yuichi Maeda, Kosuke Ebina, Ryota Hara, Sadao Jinno, Akira Onishi, Kosaku Murakami, Masao Tanaka, Hiromu Ito, Tsuneyo Mimori and Shuichi Matsuda. Does a family history of RA influence the clinical presentation and treatment response in RA? ANSWER Cohort\u2014[abstract] In: the 5th annual meeting of Japanese Society of Osteoimmunogy; 2019 June 25\u201327; Ishigaki, Okinawa, Japan. Abstract nr P2-1.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Congress abstract"}}]}}